Growing evidence on host and tumor-related features that drive resistance toward CD38 antibodies underlies differential therapeutic efficacy, and may lead to further optimization and individualization of oncological treatment for a better outcome in patients affected by different tumors and MM in particular. The gene discussed is CD38; the disease is Miyoshi myopathy.